MET and cancer: Aberrant activation of hepatocyte growth factor (HGF)/c-Met pathway due to MET gene overexpression, amplification, activating mutations, or excessive autocrine or paracrine HGF secretion have been associated with the development of several cancers such as lung, pancreas, gastric, breast, kidney, bladder, ovary, brain and prostate cancers6–9.